Regulatory action this week by the Food and Drug Administration regarding the painkiller OxyContin could help reduce some forms of abuse of the drug, but it will also prevent a generic version from being marketed.
Connect With Us on Twitter
For Op-Ed, follow @nytopinion and to hear from the editorial page editor, Andrew Rosenthal, follow @andyrNYT.
An "extended release" form of OxyContin was approved in the mid-1990s. Although the active ingredient, oxycodone, was supposed to be released gradually for patients who needed round-the-clock pain relief, some users found ways to crush, break or dissolve the tablets so that the narcotic could be taken in a big, potentially fatal dose.
In 2010, Purdue Pharma won F.D.A. approval to market a reformulated product that had the same ingredients but was harder to break or crush. It was less usable for snorting; if dissolved, it would form a gel that would be hard to inject. Purdue Pharma withdrew the old and more easily abused product from the market.
This week, just as the company's patent was set to expire, opening the way for generic competition, the F.D.A. ruled that the old formulation had been withdrawn for safety or effectiveness reasons. Generic companies, which had been poised to offer cheaper copies of the old formulation, could no longer do so.
The public can only hope that generic companies succeed in marketing their own abuse-deterrent formulations so that they can compete with Purdue Pharma's product without infringing its patents on the new formulation, which could extend until 2025. That would help keep prices down and protect the public.
Anda sedang membaca artikel tentang
Editorial: The Loss of Generic OxyContin
Dengan url
http://opinimasyarakota.blogspot.com/2013/04/editorial-loss-of-generic-oxycontin.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Editorial: The Loss of Generic OxyContin
namun jangan lupa untuk meletakkan link
Editorial: The Loss of Generic OxyContin
sebagai sumbernya
0 komentar:
Posting Komentar